Jazz Pharma says Zepzelca Phase 3 LAGOON trial misses overall survival endpoint in second-line SCLC

• Jazz reported top-line Phase 3 LAGOON results for Zepzelca in relapsed metastatic small cell lung cancer; results were presented in this update.
• The trial missed its primary overall survival goal for Zepzelca alone or with irinotecan versus investigator-choice chemotherapy.
• No new safety issues emerged; tolerability looked favorable versus the control arm, with higher side effects in the combination regimen.
• Jazz said the outcome does not affect its 2026 guidance; it will discuss post-marketing requirements for the second-line indication with the FDA.
• Strategy emphasis remains first-line maintenance use with immunotherapy, supported by the earlier IMforte study that underpinned full U.S. approval in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606120800PR_NEWS_USPR_____SF81984) on June 12, 2026, and is solely responsible for the information contained therein.